Ligachem Bio Science Co., Ltd. announced on March 18 that it will release research results for two next-generation BCMA (B-cell maturation antigen)-targeted ADC pipeline candidates (LCB14-2524, LCB14-2516), which are being developed as treatments for multiple myeloma.

Ligachem Bio to Present Preclinical Results of Next-Generation BCMA ADCs at AACR View original image

This research will be presented as a poster at the American Association for Cancer Research (AACR 2026), which will be held in San Diego, USA, from April 17 to 22, 2026 (local time). The related abstract was released on the conference website on March 17, 2026.


The BCMA ADCs announced this time are among the key projects of Ligachem Bio's ongoing 'BioBest' strategy, representing the most advanced development stage among the company's various BioBest pipelines.


In the multiple myeloma treatment market, the recent re-approval of Blenrep (belantamab mafodotin) has demonstrated the significance of BCMA-targeted therapy. However, the high ocular toxicity (keratopathy) associated with Blenrep remains an unresolved challenge. To overcome these limitations, Ligachem Bio has designed two differentiated candidates using its proprietary ADC platform, ConjuAll™, maximizing efficacy while minimizing toxicity.


The first candidate, LCB14-2524, disclosed in this abstract, is a drug that combines an antibody—engineered to enhance antibody-dependent cellular cytotoxicity (ADCC)—with Ligachem Bio's next-generation LBG (β-glucuronide) linker and an MMAF payload. The other candidate, LCB14-2516, uses a safer antibody and is equipped with a proprietary PBD prodrug payload, maximizing therapeutic efficacy. Both agents have shown significantly superior cytotoxicity and efficacy compared to the control group, Blenrep, in preclinical studies.



Ligachem Bio is currently accelerating its preparations for an IND submission to enter global clinical trials for the BCMA ADCs. Starting with this AACR presentation, the company plans to demonstrate the value of its leading BCMA ADC pipeline under the 'BioBest' strategy and rapidly advance the development of subsequent BioBest pipelines, focusing its resources on delivering safer and more potent treatment options to patients compared to existing therapies.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing